Trellis Bioscience 's CellSpot(TM) platform enables us to find rare human monoclonal antibodies. We apply the technology to develop therapies against cancer and infectious diseases, and find solutions when the immune system attacks protein therapeutics
Location: United States, California, Redwood City
Total raised: $10M
Investors 4
| Date | Name | Website |
| - | New Scienc... | newscience... |
| - | K2X | k2x.capita... |
| - | Easton Cap... | eastoncapi... |
| - | CARB-X | carb-x.org |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.02.2007 | - | $10M | - |
Mentions in press and media 2
| Date | Title | Description |
| 22.07.2017 | CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience | Development of Trellis’ monoclonal antibody (mAb) using CMC Biologics’ proprietary CHEF1® Expression Platform and Multi-column Continuous Chromatography (MCC) Technology CMC ICOS Biologics, Inc., a global leader in clinical and commercial ... |
| 14.02.2007 | Trellis Bioscience, cell monitoring company, raises $10M | Trellis Bioscience, a South San Francisco company that monitors cells at the individual level to assess what sort of treatments to give people, said it has raised $10 million in a second round of financing. Novartis Bioventures led the roun... |